What are your research interests?
- Circulating biomarkers of disease, disease susceptibility, and response to treatment
- Normal and pathological effects of circulating microvesicles and their cargo
Why did you get into research?
I have always been fascinated by the ingenious complexities within the human body that are invisible to the naked eye. The challenge of deciphering them is my driving force.
What would be the ultimate goal for your research?
I would love to be able to use a single blood sample to determine a person's health status, risk of disease, diagnosis of any disease they may not be aware of, and ultimately what treatment will cure them without causing any harm.
Dr Lincz has been employed by the Calvary Mater Newcastle (CMN) Hospital in the Hunter Haematology Research Group since 1998 where she is presently the Senior Research Officer and holds a conjoint Associate Professor position at the University of Newcastle’s School of Biomedical Sciences and Pharmacy. Dr Lincz’s research interests combine a background in molecular biology with current knowledge of clinical haematology and a passion for discovering biomarkers of disease and response to treatment.
Dr Lincz has a strong background in cancer biology, having been awarded her PhD in 1998 for work examining the role of cellular adhesion and three-dimensional structures in preventing programmed cell death in colon cancer. In order to support what is now a more translational form of research, she went on to complete a Graduate Diploma in Clinical Epidemiology (Molecular Genetics) in 2007 at the University of Newcastle. Dr Lincz has taken a more recent interest in thrombosis and coagulation, as evidenced by her publications of the past five years, her NHMRC grants and current collaborations with the International Stroke Consortium and Subcommittee of the International Society on Thrombosis and Haemostasis.
Dr. Lincz is Chairperson for the CMN Research Committee (since 2006), peer reviews for many funding bodies and publishers, and has successfully supervised both undergraduate and higher research degrees (currently 2 PhD students). She has been invited to present her work on microvesicles at national and international conferences, and has published numerous peer-reviewed articles in the field.
I am currently analysing circulating microparticles from the blood of people with various diseases in order to determine how they contribute to disease; with the hopes of one day finding a way to stop them.
- Micovesicle analysis by flow cytometry
- Nanosight nanoparticle tracking analysis
- Molecular and cellular biology
- Statistical analysis
- HMRI Cancer Research Group
- Priority Research Centre for Cancer
- Hunter Cancer Research Alliance
- UoN School of Biomedical Sciences and Pharmacy
- Chairperson, Newcastle Mater Hospital Research Committee
- Hunter HUB steering committee, NSW Research HUBS initiative
- Australasian Leukaemia and Lymphoma Group (ALLG)
- Australian Society for Thrombosis and Haemostasis (ASTH)
- International Society on Thrombosis and Haemostasis (ISTH).
- International Society for Extracellular Vesicles (ISEV)
Cancer is the most common cause of childhood disease-related deaths, with leukaemia the most common childhood cancer in Australia. The two most common forms of leukaemia in children are acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). Whilst remission is achievable in over 95% of ALL cases, 1/3 of patients will relapse within 5 to 10 years, and these children will not be long-term survivors. AML accounts for 20% of all childhood leukaemias, and the outlook for children diagnosed with AML is much worse, with only approximately half of children surviving for 5 years post-diagnosis.
Dr James Lynam, Dr Jennette Sakoff, Professor Jenny Martin, Dr Lisa Lincz, Dr Mike Fay, Giovana Celli Marchett, Dr Peter Galettis
Annually there are 2,000 new cases of brain cancer in Australia. Prognosis for people with brain cancer is dire. It is the highest cause of death in 0-39 age group with a 5-year survival rate of 19%. Brain cancer results in 5,000 hospitalisations per year (average stay 12.5 days, the longest of any cancer) and has the highest lifetime cost per patient of $1.89m .
Dr James Lynam, Jennette Sakoff, Jenny Martin, Lisa Lincz, Mike Fay, Giovana Celli Marchett, Peter Galettis
Annually there are 2,000 new cases of brain cancer in Australia. Prognosis for people with brain cancer is dire. It is the highest cause of death in 0-39 age group with a 5-year survival rate of 19%. Brain cancer results in 5,000 hospitalisations per year (average stay 12.5 days, the longest of any cancer) and has the highest lifetime cost per patient of $1.89m.
Dr Lisa Lincz, Dr Rick Thorne
The aim of this research is to understand how diabetes cause complications in other parts of the body.
Associate Professor Eugene Nalivaiko, Lisa Lincz
Dr Rick Thorne, Lisa Lincz